STRATINC Interreg III C: Tenerife meeting Knut Halvorsen Manager Oslo Teknopol IKS 7th and 8 th April 2005 The Oslo Biotech Cluster.

STRATINC Interreg III C: Tenerife meeting

Knut Halvorsen Manager Oslo Teknopol IKS7th and 8 th April 2005

The Oslo Biotech Cluster

Background

• High indirect independency on petroleum (”Kuwait” economy)

• Science based region (50% of Norways R&D)

• Low innovation rate (2 – 3% from R&D)

The process – RITTS

• RITTS – Negotiations: Fall 1998• Stage 0: Through 1999: Concensus• Stage 1: Though 2000 : Analysis• Stage 2: First half 2001: Implementation• Result: June 2001: Final report

• Methodology: Internal and external experts

• Organisation: Integrated in the main decision structure in the region.

Defintion: Technopole

• « Supporting a territorial development policy based on innovation, a technopole favours cross-fertilisation. Creation of innovative activities, animation and networking of competences, territorial marketing, are the components of the technopolitan dynamics »(France Technopoles Entreprises Innovation)

Oslo Teknopol - organisation

• Owned by Oslo and County of Akershus

• 13 employees (social sciences)• Budget of NOK 16 mill.• Theoretical approach: Clusters • Strategy: Technopole • Methodology: Governance• Vision: Oslo Teknopol shall – in

cooperation with others – work towards making the Osloregion one of the most innovative regions in Europa by 2010.

The strategies: ”Bottom up” and Clusters

• Martime,• Energy and Environment• ICT• Life Science, • Art and Design

Life science

Maritime

Art, design, film & architecture

Energy & environmental technology

Information & communication

technology

Clusters, interfaces and facilitators

TTO

Innovation companies

Innovation networks

Reasearch Parks & incubators

Life Science in the Oslo region – key players

Symbols: Universities/higher education insitutions: 3

University hospitals: 5

Resarch instiutions including Centres of Excellence: 10

Science Parks: 2

Commercial inst: 3

Companies: 1 157

Regional networks: 3

Norwegian Bioindustry Association

Medcoast Scandinavia

Oslo/Göteborg

Medicon Valley

Stockholm/Copenhagen

4. Life science

Leder: Professor Kaare Norum

MedCoast Scandinavia OptiNose AS

Glaxo Smith Kline Clavis Pharma

Astra Zeneca Dynal Biotech ASA

GE – Vingmed Ultrasound GenoMar ASA

Biomedisinsk Innovasjon Dag Dvergsten AS

Birkeland Innovasjon PubGene

Bioteknologisenteret i Oslo Interagon

Norges Vetrinærhøgskole Sim Surgery

Høgskolen i Akershus

Radiumhospitalets Forskningsstifelse

Fondsfinans

OT ved Knut Halvorsen og Therese HolmThorvaldsen

Summary, challenges to be discussed

• Complex institutional structure

• Non codified knowledge• Do not share core

business ideas• Trust (F2F meetings)• PSIPs is one of many

tools.